Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission

Inclusion Criteria: * Diagnosis of acute myeloid leukemia (AML) according to the 2008 criteria of the World Health Organization (WHO). * all French-American-British (FAB) subtypes, except: \- M3 (acute promyelocytic leukemia) * all cases of de novo AML or secondary AML with ≥ 20 % blasts in peripheral blood and/or bone marrow, except: * AML secondary to myeloproliferative neoplasms (MPN) * AML secondary to exposure of leukemogenic agents (t-AML) unless treated with CPX-351 chemotherapy or hypomethylating agents combined with venetoclax. * Completion of one of the following treatment options: * I) Intensive chemotherapy: * (1) at least one cycle of induction chemotherapy and one cycle of consolidation chemotherapy (low-dose cytarabine as consolidation therapy is allowed) OR * (2) one to two cycles of CPX-351 induction treatment and up to two cycles of CPX-351 consolidation treatment OR * II) Low-intensity chemotherapy: * (3) at least two cycles to maximum six cycles of hypomethylating agents whether or not combined with venetoclax OR * (4) at least two cycles to maximum six cycles of low-dose cytarabine combined with venetoclax; * resulting in: * morphological complete remission (CR), i.e. bone marrow blast count \<5% with neutrophil count \>1000 cells/µL and platelet count \>100,000 cells/µL OR * morphological complete remission with incomplete blood recovery (CRi), i.e. bone marrow blast count \<5% with neutrophil count \…